At the beginning of a treatment cycle, if a treatment delay is indicated for either capecitabine or docetaxel, then administration of both agents should be delayed until the requirements for restarting both drugs are met. Capecitabine (Xeloda) to Treat Breast Cancer The chemotherapy drug capecitabine was approved by the U.S. Food and Drug Administration (FDA) on June 15, 2005, and it is commercialized under the brand name Xeloda by Hoffman-LaRoche. The committee was most strongly influenced by the phase II trial by Blum et al. IN COMBINATION WITH DOCETAXEL (Metastatic Breast Cancer): Dose modifications of capecitabine for toxicity should be made according to the monotherapy schedule above. 1 The majority of these deaths occur in women with metastatic breast cancer (MBC), reflecting the incurability of MBC and the need for improved treatment. e12566. Breast cancer causes approximately 40,000 deaths annually in the United States. Pre-medication, according to the docetaxel labeling, should be started prior to docetaxel administration for patients … Background: Capecitabine is an active agent in the treatment of advanced breast cancer (ABC). Our primary objective was to compare the standard dosing of capecitabine (Arm A: days 1-14 on 21-day cycle) to biweekly dosing (Arm B: days 1-7 and 15-21 on 28-day cycle) using retrospective data analysis. Breast cancer is the most prevalent malignancy in women and metastatic breast cancer is a leading cause of mortality, accounting for more than 400,000 deaths annually worldwide. The expert reference panel supported publication of the protocol on the basis of the information summarised below. A search of the literature did not find strong evidence to support the use of capecitabine in the second line treatment of metastatic breast cancer. Introduction. Purpose Capecitabine is widely used as a single agent on a 21-day cycle in the management of metastatic breast cancer (MBC).
Methods: The study population included 162 pts retrospectively analyzed with ABC treated with capecitabine between 2006 and 2015 at our Institute. In Combination With Docetaxel (Metastatic Breast Cancer) In combination with docetaxel, the recommended dose of XELODA is 1250 mg/m 2 twice daily for 2 weeks followed by a 1-week rest period, combined with docetaxel at 75 mg/m 2 as a 1-hour intravenous infusion every 3 weeks. Methods 166 patients with MBC treated with … It is commonly administered at the approved dosage of 1250 mg/m2 twice daily for 2 weeks followed by 1 week rest period. Both capecitabine and bevacizumab are established agents in the treatment of metastatic breast cancer, but until recently clinical data supporting their use in combination were limited.